Abstract A72: HESA-A: Bright prospect for prevention and treatment of malignancies

Cancer is one of the leading causes of death in the world, particularly in developing countries that represents a tremendous burden on patients, families and societies. More than 70% of all cancer deaths occur in low and middle income countries, where resources available for prevention, diagnosis and treatment of cancer are limited or nonexistent. The effect of different types of drugs on quality of life and survival of end-stage cancer patients has been investigated, however many side effects of these drugs limited their usage. HESA-A is a compound of natural origin, consisting of rare elements and organic materials, which in several animal and cellular studies have shown powerful anticancer effects and less toxicity on normal cells. The aim of the present study was to investigate the efficacy and safety of HESA-A in the prevention and treatment of Osteosarcoma as a lethal malignancy entire the world.

In an experimental study, 40 rabbits were randomly allocated to one of two groups of administered HESA-A (study group) and placebo (control group) for 10 days. After this time, carcinogen agent was inserted under the periost for Osteosarcoma formation and bone radiography and magnetic resonance imaging were performed after three months. Also, cases were followed for 6 months.

In study group, among 20 rabbits, pathological bone changes were not detected in 16 cases and after 6 months following-up, all cases were alive and no changes in their appetite and weight were observed. Besides, in placebo group, all cases suffered from Osteosarcoma. In the second stage, control cases were divided into two groups (10 rabbits were treated with HESA-A and 10 cases as non-treated group) and followed-up for 6 months. All non-treated cases were died, whereas treated cases were survived and their appetite and weight were improved.

This study proved the preventive and curative effects of HESA-A on Osteosarcoma and create a bright prospect for the future in the treatment of cancers.

Citation Information: Cancer Prev Res 2008;1(7 Suppl):A72.